Stem Cell and Cancer Biology Program

项目主任/首席调查员(最后、第一、中间)：朱 干细胞和癌症生物学计划--项目摘要/摘要 干细胞和癌症生物学(SCCB)计划的首要目标是提供基本的见解 进入促进癌症进化、进展和治疗耐药的基本细胞和分子机制 这使得识别新的抗癌策略成为可能。为了实现这一使命，该计划有三个 具体目标是：(1)发现恶性肿瘤(干细胞)细胞进化的潜在机制； (2)描述癌症进展和治疗耐药性的驱动因素；以及(3)描述主要的 建立和管理细胞分化和同一性的机制。成功的战略 执行这项任务需要基础、临床前和临床/翻译研究的参与。这个 SCCB计划关键地依赖于各种广泛的科学专业知识，包括高度 集中的分子和细胞生理机制，并通过各种模式生物得到证实 和站台。它还依赖于与其他MECC研究项目的合作，包括癌症 具有翻译能力的SCCB成员的新发现的临床翻译治疗计划 申请。集中式MECC支持，特别是共享资源，例如(但不限于)动物 模型共享资源、生物统计学共享资源、基因组学共享资源、分析成像 设施、流式细胞仪共享资源、肿瘤生物库共享资源，极大地方便了， 简化和加强SCCB研究。 OMB编号0925-0001/0002(截至2023年2月28日批准的第03/2020版)页面

Program Director/Principal Investigator (Last, First, Middle): Chu, Edward STEM CELL AND CANCER BIOLOGY PROGRAM - PROJECT SUMMARY/ABSTRACT The overarching goal of the Stem Cell and Cancer Biology (SCCB) Program is to provide fundamental insights into the basic cell and molecular mechanisms facilitating cancer evolution, progression and therapy resistance which enable the identification of novel anti-cancer strategies. To achieve this mission, the Program has three specific aims, which are to: (1) discover mechanisms underlying the evolution of malignant cancer (stem) cells; (2) delineate drivers of cancer progression and therapy resistance; and (3) characterize the principal mechanisms establishing and governing cellular differentiation and identity. The strategy for successfully carrying out this mission requires the involvement of basic, preclinical, and clinical/translational research. The SCCB Program critically relies on a diverse and broad spectrum of scientific expertise encompassing highly focused molecular and cell physiological mechanisms, and is substantiated through various model organisms and platforms. It also relies upon collaborations with other MECC research programs, including the Cancer Therapeutics Program for clinical translation of new discoveries by SCCB members that have translational applications. Centralized MECC support, particularly Shared Resources, such as (but not limited to) the Animal Model Shared Resource, Biostatistics Shared Resource, Genomics Shared Resource, Analytical Imaging Facility, Flow Cytometry Shared Resource, and Cancer Biorepository Shared Resource, greatly facilitates, streamlines, and enhances SCCB research. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page